We would love to hear your thoughts about our site and services, please take our survey here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Morning BV, I found a copy of the TG notes, and yes, it was Fiona who answered a question about weekly dosing:
“Now that we have seen how safe AVA6000 is we know we could do more frequent dosing. It’s important to remember we are not dosing Dox but AVA6000 which is a targeted version of DOX and dosing every two weeks may give better outcomes for patients. Weekly dosing could increase toxicity and fatigue, so it may be considered in the future but we have decided to trial fortnightly dosing.” (18th October 2023)
https://x.com/sarahjean191/status/1717536397416869977?s=61&t=yGNoQ6Xj0Lw6rjPJMTuiZA
( I am not Sarah Stevens, I just remember her posting the notes)
I think going for a more frequent dosing was an obvious decision, not necessarily influenced by any outsiders, be that the FDA or prospective partners, as more frequent, lower doses of doxorubicin are already a thing in the clinic - Pfizer's ⅓-strength dose given weekly for instance. I'd be very disappointed if Avacta weren't already thinking seriously about it by Science Day but there is a process and certain investigative steps to be followed. Didn't FMcL say somewhere (perhaps in the TG notes?) that weekly dosing was a step too far? It wasn't ruled out completely. A successful fortnightly dosing will inform any decisoin about weekly dosing in the future much more than the 3-weekly dosing could.
The 2 weekly trial has just started and cohort 2 hopefully starting end of the month. I suspect prelims on Monday 29 April and he’ll surely need a miracle from now to the AGM to save his bacon. He’ll need to share price a fair whack higher before AGM or else I suspect many will vote for him to be ousted.
Notice of prelims Monday next week and safety committee happy to process RNS end of next week. A bonus would be that a patient/s have received first dose.
I’m just pleased it’s on my radar and also pleased I took advantage and bought a few more at 50p (not pleased at the 50p fund raise though). Two weeks to go until Al explains his reasoning and I think he has timed it to coincide with the end of the two weekly trial (which if this was influenced by the FDA could mark news that inspires a significant upturn in SP🤞). GLA
Toukankahmoon wrote "What I don’t understand is that it isn’t on Cancer UK’s radar"
Firstly, how do you know it isn't? Do please tell us your inside knowledge.
Secondly, if it were, what difference would that make to Avacta or Cancer UK?
@JWBellamy, that's interesting. Which rampers are you referring to? Can you name any of them?
Cj62,
With respect, go and read up on FDA Clinical Trial phases and what each phase is meant to verify.
Doh.
Interesting to note that you're still a twat.
Interesting to see that loads of the well known rampers that were here above £1 are no longer here
Thorono lol. And here’s another fool.
Why would they announce something 'to the media'?
It either stands up to scientific scrutiny and the regulatory authorities or it doesn't.
Not that I don't have time for Richard Madely you understand but really?
Jwb go and do one you bloody fool !
When the directors buy £500,000-£1m here I will buy some.
Until then, I will remain bearish
HEMO is a complete dog, vlad hates PIs even more than Al and somehow has even less financial aptitude. He pretty much is the company, and at his age it makes it especially high risk, has never kept a deadline and it still hasn't dosed first patient, hence extremely low SP compared to peers. As soon as it rises 100% expect another placing. Someone in daily mail was duped in to the 2p placing and is now wanting out.
Anyway, back to Avacta. I think they'll wait till phase 2 is progressing before announcing anything to the media otherwise they would have done so already. Something tied in with a licence deal would be nice for maximum effect, perhaps a patient with stable disease giving permission to discuss their case, but I'm not sure they have the nous for that. Just prepared to be underwhelmed with this share.
Yep you are quite correct. As the missus says I cannot multi task but you got the drift 😵💫
"remember phase 1 was all about efficacy"
Did you mean NOT. It's just safety and tolerability.
So the efficacy seen is pretty amazing.
End of April
Alderbaran when more conclusive data is produced , remember phase 1 was all about efficacy. It appears the patients have been cherry picked for the 2W phase with the 1st cohort due to produce results by April , even these won't be splashed around the media but if we get to say end off cohort 3 and the data/efficacy results are as we hope. I am assuming then have enough to be truly confident of the results then the main stream media will be given the good news. End of Q3 for me
WET Cancer go away
Give it a rest wynbore. Time for you to Move on to another BB. You’ve done best here peddling your subtle negative rambling nonsense over the years !
Nobody listening now mate ! We all no it works
And only patience is now required
I think the trial to date has to be seen in context with what AS said in the Q&A when he was asked have AVCT done enough to let potential interested parties know of this Holy Grail development and he said no (which at the time I was pretty unimpressed with), and siad maybe letting cancer patient frpiup's know might of be an area they could target.
Either this means the data to date is so "weak" inasmuch as its just about safety and we are all jumping the gun here on circumstantial efficay results, or they have missed ahuge trick.
I am thinking its a bit of both but had AVCT kept these particular patient groups informed from the begining then getting volunteers for the next cohorts and stages might have gone a tad quicker.
Anyway we are where we are...
It is obvious now the science works I think everyone agrees on that
So when do Avacta actually let the world know?
I imagine it will be when the 1st line patients they are treating all are seeing stable disease or tumour regression so can make a splash in the media with some human stories
When will that be ? are the 2 weekly dosed patients taking AVa6000 as a first line treatment?